Sheela Nagarajan, Jose Manonmani Alvin, Sathyamurthy Duraiswami, Kumar Balasubramanian Nandha
Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode, Tamil Nadu, India.
Iran J Kidney Dis. 2013 Mar;7(2):117-23.
Diabetic nephropathy is the major cause of end-stage renal disease worldwide. Silymarin is a flavonoid mixture obtained from Silybum marianum. Various preclinical and clinical studies have revealed that it has antidiabetic activity. The objective of this study was to evaluate the effect of silymarin on type 2 diabetic nephropathy in rats.
Non-insulin-dependent diabetes mellitus was induced in overnight-fasted male albino Wistar rats by an intramuscular injection of streptozotocin and nicotinamide. Eighteen rats with diabetic nephropathy and 6 rats without induced nephropathy were divided into 4 groups, each containing 6 animals. Group 1 was the normal control and group 2 was the DM control. Groups 3 and 4 were rats with diabetic nephropathy that received 60 mg/kg and 120 mg/kg of silymarin for 60 days.
At the end of the study period, the diabetic control group had significantly higher blood glucose, glycosylated hemoglobin, urine volume, serum uric acid, and urine albumin levels when compared to the normal control group. Silymarin-treated groups showed significantly lower levels of blood glucose, glycosylated hemoglobin, urine volume, serum creatinine, serum uric acid, and urine albumin, when compared to the diabetic control group. Histopathological studies reports strongly supported the protective effect of silymarin.
These findings suggest that silymarin has protective effects for kidneys affected by type 2 diabetes mellitus. If the safety and efficacy is confirmed in humans, silymarin will be a good medication to prevent nephropathy-induced premature death in diabetic patients.
糖尿病肾病是全球终末期肾病的主要病因。水飞蓟素是从水飞蓟中提取的一种黄酮类混合物。各种临床前和临床研究表明它具有抗糖尿病活性。本研究的目的是评估水飞蓟素对大鼠2型糖尿病肾病的影响。
对过夜禁食的雄性白化Wistar大鼠进行肌肉注射链脲佐菌素和烟酰胺诱导非胰岛素依赖型糖尿病。18只患有糖尿病肾病的大鼠和6只未诱导出肾病的大鼠被分为4组，每组6只动物。第1组为正常对照组，第2组为糖尿病对照组。第3组和第4组是患有糖尿病肾病的大鼠，分别接受60mg/kg和120mg/kg的水飞蓟素治疗60天。
在研究期结束时，与正常对照组相比，糖尿病对照组的血糖、糖化血红蛋白、尿量、血清尿酸和尿白蛋白水平显著更高。与糖尿病对照组相比，水飞蓟素治疗组的血糖、糖化血红蛋白、尿量、血清肌酐、血清尿酸和尿白蛋白水平显著更低。组织病理学研究报告有力地支持了水飞蓟素的保护作用。
这些发现表明水飞蓟素对受2型糖尿病影响的肾脏具有保护作用。如果在人体中证实其安全性和有效性，水飞蓟素将是预防糖尿病患者因肾病导致过早死亡的一种良好药物。
